Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank10
Year-over-Year Change
Year-over-year free cash flow growth rate
Percentile
P10
Near historical low
vs 3Y Ago
-4.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -69.41% |
| Q3 2025 | 22.88% |
| Q2 2025 | 19.17% |
| Q1 2025 | 58.17% |
| Q4 2024 | -62.21% |
| Q3 2024 | 133.99% |
| Q2 2024 | -461.96% |
| Q1 2024 | 499.55% |
| Q4 2023 | -85.62% |
| Q3 2023 | 14.24% |
| Q2 2023 | 25.30% |
| Q1 2023 | -17.90% |
| Q4 2022 | 15.92% |
| Q3 2022 | -17.05% |
| Q2 2022 | 21.72% |
| Q1 2022 | -4.35% |
| Q4 2021 | 6.68% |
| Q3 2021 | 450.48% |
| Q2 2021 | -129.36% |
| Q1 2021 | 91.53% |
| Q4 2020 | -39.45% |
| Q3 2020 | -28.19% |
| Q2 2020 | 28.18% |
| Q1 2020 | 85.50% |
| Q4 2019 | 38.24% |
| Q3 2019 | -30.60% |
| Q2 2019 | 45.85% |
| Q1 2019 | 2.64% |
| Q4 2018 | -17.08% |
| Q3 2018 | 23.40% |
| Q2 2018 | 30.76% |
| Q1 2018 | 21.05% |
| Q4 2017 | 29.83% |
| Q3 2017 | -13.48% |
| Q2 2017 | -35.48% |
| Q1 2017 | 95.94% |
| Q4 2016 | 150.97% |
| Q3 2016 | 107.57% |
| Q2 2016 | 192.00% |
| Q1 2016 | -263.16% |